Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission

Haematologica. 2004 Aug;89(8):ECR25.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Bone Marrow / pathology
  • Chronic Disease
  • Humans
  • Hypereosinophilic Syndrome / blood*
  • Hypereosinophilic Syndrome / drug therapy*
  • Hypereosinophilic Syndrome / pathology
  • Imatinib Mesylate
  • Male
  • Middle Aged
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Receptor, Platelet-Derived Growth Factor alpha / blood*
  • Treatment Outcome
  • mRNA Cleavage and Polyadenylation Factors / blood*

Substances

  • Antineoplastic Agents
  • Benzamides
  • FIP1L1 protein, human
  • Piperazines
  • Pyrimidines
  • mRNA Cleavage and Polyadenylation Factors
  • Imatinib Mesylate
  • Receptor, Platelet-Derived Growth Factor alpha